Page 95 - Haematologica Vol. 109 - July 2024

ARTICLE - Targeting TNF/IL-17/MAPK in hE2A-PBX1 zebrafish
H. Luo et al.
3. Amor Vigil AM, Fernández Martínez L, Díaz Alonso CA, et al. Transcripto E2A-PBX1 en paciente pediátrico con leucemia aguda híbrida linfoide b/mieloide. Rev Cubana Hematol Inmunol Hemoter. 2017;33(3):95-101.
4. Troussard X, Rimokh R, Valensi F, et al. Heterogeneity of t(1;19) (q23;p13) acute leukaemias. French Haematological Cytology Group. Br J Haematol. 1995;89(3):516-526.
5. Hong Y, Zhao X, Qin Y, et al. The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2018;97(9):1547-1554.
6. Irving JAE, Enshaei A, Parker CA, et al. Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2016;128(7):911-922.
7. Hunger SP. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood. 1996;87(4):1211-1224.
8. Zhao W, Li Z-g, Gao C. Detection of E2A/PBX1 fusion gene and its clinical significance in childhood acute lymphoblastic leukemia. Zhonghua Er Ke Za Zhi. 2008;46(7):550-551.
9. Jia M, Hu B-F, Xu X-J, Zhang J-Y, Li S-S, Tang Y-M. Clinical features and prognostic impact of TCF3-PBX1 in childhood acute lymphoblastic leukemia: a single-center retrospective study of 837 patients from China. Curr Probl Cancer. 2021;45(6):100758.
10. Diakos C, Xiao Y, Zheng S, Kager L, Dworzak M, Wiemels JL. Direct and indirect targets of the E2A-PBX1 leukemia-specific fusion protein. PLoS One. 2014;9(2):e87602.
11. Murre C. Regulation and function of the E2A proteins in B cell development. In: Gupta S, Alt F, Cooper M, Melchers F, Rajewsky K, eds. Mechanisms of lymphocyte activation and immune regulation Xi. B Cell Biology. Boston, MA: Springer; 2007. p. 1-7.
12. Semerad CL, Mercer EM, Inlay MA, Weissman IL, Murre C. E2A proteins maintain the hematopoietic stem cell pool and promote the maturation of myelolymphoid and myeloerythroid progenitors. Proc Natl Acad Sci U S A. 2009;106(6):1930-1935.
13. Malouf C, Ottersbach K. Molecular processes involved in B cell acute lymphoblastic leukaemia. Cell Mol Life Sci. 2018;75(3):417-446.
14. Aspland SE, Bendall HH, Murre C. The role of E2A-PBX1 in leukemogenesis. Oncogene. 2001;20(40):5708-5717.
15. Kamps MP, Baltimore D. E2A-Pbx1, the t(1;19) translocation protein of human pre-B-cell acute lymphocytic leukemia, causes acute myeloid leukemia in mice. Mol Cell Biol. 1993;13(1):351-357.
16. Kamps MP, Wright DD. Oncoprotein E2A-Pbx1 immortalizes a myeloid progenitor in primary marrow cultures without abrogating its factor-dependence. Oncogene. 1994;9(11):3159-3166.
17. Dedera DA, Waller EK, LeBrun DP, et al. Chimeric homeobox gene E2A-PBX1 induces proliferation, apoptosis, and malignant lymphomas in transgenic mice. Cell. 1993;74(5):833-843.
18. Bijl J, Sauvageau M, Thompson A, Sauvageau G. High incidence of proviral integrations in the Hoxa locus in a new model of E2a-PBX1-induced B-cell leukemia. Genes Dev. 2005;19(2):224-233.
19. Sera Y, Yamasaki N, Oda H, et al. Identification of cooperative genes for E2A-PBX1 to develop acute lymphoblastic leukemia. Cancer Sci. 2016;107(7):890-898.
20. Sykes DB, Kamps MP. E2a/Pbx1 induces the rapid proliferation of stem cell factor-dependent murine pro-t cells that cause acute T-lymphoid or myeloid leukemias in mice. Mol Cell Biol.
2004;24(3):1256-1269.
21. Hyndman BD, LeBrun DP. E2A-PBX1. In: Schwab, M. (eds)
Encyclopedia of cancer. Springer, Berlin, Heidelberg; 2009.
p. 935-936.
22. van de Ven C, Boeree A, Stalpers F, Zwaan CM, Den Boer ML.
Ibrutinib is not an effective drug in primografts of TCF3-PBX1.
Transl Oncol. 2020;13(10):100817.
23. Eldfors S, Kuusanmaki H, Kontro M, et al. Idelalisib sensitivity
and mechanisms of disease progression in relapsed TCF3-PBX1
acute lymphoblastic leukemia. Leukemia. 2017;31(1):51-57. 24. Rasighaemi P, Basheer F, Liongue C, Ward AC. Zebrafish as a
model for leukemia and other hematopoietic disorders. J
Hematol Oncol. 2015;8(1):1-10.
25. Ali S, Champagne DL, Spaink HP, Richardson MK. Zebrafish
embryos and larvae: a new generation of disease models and drug
screens. Birth Defects Res C Embryo Today. 2011;93(2):115-133. 26. Bentley VL, Veinotte CJ, Corkery DP, et al. Focused chemical
genomics using zebrafish xenotransplantation as a pre-clinical therapeutic platform for T-cell acute lymphoblastic leukemia. Haematologica. 2015;100(1):70-76.
27. Haney MG, Moore LH, Blackburn JS. Drug screening of primary patient derived tumor xenografts in zebrafish. J Vis Exp. 2020(158):10.
28. Chauvigné F, Yilmaz O, Ferré A, et al. The vertebrate Aqp14 water channel is a neuropeptide-regulated polytransporter. Commun Biol. 2019;2(1):462.
29. Jin H, Sood R, Xu J, et al. Definitive hematopoietic stem/ progenitor cells manifest distinct differentiation output in the zebrafish VDA and PBI. Development. 2009;136(4):647-654.
30. Jin H, Li L, Xu J, et al. Runx1 regulates embryonic myeloid fate choice in zebrafish through a negative feedback loop inhibiting Pu.1 expression. Blood. 2012;119(22):5239-5249.
31. Pruvot B, Jacquel A, Droin N, et al. Leukemic cell xenograft in zebrafish embryo for investigating drug efficacy. Haematologica. 2011;96(4):612-616.
32. Zeng Y, Zhang X, Lin D, et al. A lysosome-targeted dextran- doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia. J Hematol Oncol. 2021;14(1):1-6.
33. Khan N, Mahajan NK, Sinha P, Jayandharan GR. An efficient method to generate xenograft tumor models of acute myeloid leukemia and hepatocellular carcinoma in adult zebrafish. Blood Cells Mol Dis. 2019;75:48-55.
34. Xu J, Du L, Wen Z. Myelopoiesis during zebrafish early development. J Genet Genomics. 2012;39(9):435-442.
35. LeBrun DP. E2A basic helix-loop-helix transcription factors in human leukemia. Front Biosci. 2003:8:s206-s222.
36. Baker WJ, Royer GL, Jr., Weiss RB. Cytarabine and neurologic toxicity. J Clin Oncol. 1991;9(4):679-693.
37. Ota K. [Cytarabine]. Gan To Kagaku Ryoho. 1987;14(10):2983-2987. Japanese.
38. Magina KN, Pregartner G, Zebisch A, et al. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. Blood. 2017;130(7):946-948.
39. Zeidner JF, Karp JE. Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia. Leuk Res. 2015;39(12):1312-1318.
40. Chen KTJ, Militao GGC, Anantha M, Witzigmann D, Leung AWY, Bally MB. Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia. J Control Release. 2021;333:246-257.
41. Sood R, Kamikubo Y, Liu P. Role of RUNX1 in hematological malignancies. Blood. 2017;129(15):2070-2082.
Haematologica | 109 July 2024
2109